Table 3 Cardiovascular outcomes occurring after a first within-trial nonfatal myocardial infarction in those pretreated or not pretreated with a dipeptidyl peptidase-4 inhibitor (DPP-4i) (on-treatment sensitivity analysis)
|  | DPP-4i treated n = 249 | Not DPP-4i treated n = 341 | Unadjusted hazard ratio (95% CI) | P-value | Adjusted hazard ratio (95% CI) | P-value | ||
|---|---|---|---|---|---|---|---|---|
No. (%) | Events per 100 patient-years | No. (%) | Events per 100 patient-years | |||||
Cardiovascular death or hospitalization for heart failure | 45 (18.1) | 11.9 | 62 (18.2) | 13.3 | 0.91 (0.62–1.34) | 0.63 | 0.95 (0.64–1.43) | 0.82 |
Cardiovascular death | 25 (10.0) | 6.2 | 40 (11.7) | 8.1 | 0.78 (0.47–1.29) | 0.34 | 0.75 (0.44–1.26) | 0.27 |
Hospitalization for heart failure | 27 (10.8) | 7.2 | 30 (8.8) | 6.4 | 1.15 (0.68–1.94) | 0.60 | 1.34 (0.77–2.33) | 0.31 |
New onset heart failure | 16 (6.4) | 4.0 | 20 (5.9) | 4.1 | 1.05 (0.54–2.05) | 0.88 | 1.34 (0.64–2.79) | 0.44 |
Cardiovascular death, hospital admission for heart failure, new heart failure, acute myocardial infarction, stroke or new-onset atrial fibrillation | 87 (34.9) | 28.8 | 120 (35.2) | 31.8 | 0.92 (0.70–1.22) | 0.56 | 0.95 (0.71–1.27) | 0.72 |
Further acute myocardial infarction | 46 (18.5) | 7.2 | 63 (18.5) | 7.3 | 0.97 (0.66–1.42) | 0.89 | 0.99 (0.67–1.46) | 0.95 |
All-cause death | 37 (14.9) | 8.9 | 49 (14.4) | 9.9 | 0.94 (0.61–1.44) | 0.77 | 0.91 (0.58–1.43) | 0.68 |